These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 32937002)

  • 1. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
    Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
    Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A.
    Holstein K; Albisetti M; Bidlingmaier C; Halimeh S; Heine S; Klamroth R; Königs C; Kurnik K; Male C; Oldenburg J; Streif W; Wermes C; Escuriola-Ettingshausen C;
    Hamostaseologie; 2020 Dec; 40(5):561-571. PubMed ID: 32588417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.
    Jiménez-Yuste V; Rodríguez-Merchán EC; Matsushita T; Holme PA
    Haemophilia; 2021 Jul; 27(4):519-530. PubMed ID: 33988293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Coppola A; Castaman G; Santoro RC; Mancuso ME; Franchini M; Marino R; Rivolta GF; Santoro C; Zanon E; Sciacovelli L; Manca S; Lubrano R; Golato M; Tripodi A; Rocino A;
    Haemophilia; 2020 Nov; 26(6):937-945. PubMed ID: 33094880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 10. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
    Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
    Carcao M; Escuriola-Ettingshausen C; Santagostino E; Oldenburg J; Liesner R; Nolan B; Bátorová A; Haya S; Young G;
    Haemophilia; 2019 Jul; 25(4):676-684. PubMed ID: 31033112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab for the treatment of haemophilia A: a narrative review.
    Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
    Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms.
    Lillicrap D; Fijnvandraat K; Young G; Mancuso ME
    Expert Rev Hematol; 2020 Apr; 13(4):313-321. PubMed ID: 32186928
    [No Abstract]   [Full Text] [Related]  

  • 20. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
    Meeks SL; Zimowski KL
    Haemophilia; 2024 Apr; 30 Suppl 3():95-102. PubMed ID: 38539060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.